RCM
NVO

Raleigh Capital Management’s Novo Nordisk NVO Stock Holding History

Raleigh Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-72
Closed -$2.65K – 713
2026
Q1 		$2.65K Buy
+72
New +$3.41K ﹤0.01% 490
2025
Q1 		– Sell
-92
Closed -$7.87K – 873
2024
Q4 		$7.87K Hold
92
– – ﹤0.01% 641
2024
Q3 		$10.9K Buy
92
+1
+1% +$133 ﹤0.01% 573
2024
Q2 		$13K Hold
91
– – 0.01% 521
2024
Q1 		$11.7K Hold
91
– – 0.01% 530
2023
Q4 		$9.39K Hold
91
– – ﹤0.01% 605
2023
Q3 		$8.26K Buy
91
+1
+1% +$88 ﹤0.01% 582
2023
Q2 		$7.32K Hold
90
– – ﹤0.01% 550
2023
Q1 		$7.16K Buy
+90
New +$6.38K ﹤0.01% 565

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Raleigh Capital Management's NVO Position: Q2 2026 in Review

Raleigh Capital Management sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 72 shares — an estimated $2.65K sold.

Raleigh Capital Management first reported a position in NVO in Q1 2023 and held it in 9 quarters. The position peaked at $13K in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Raleigh Capital Management reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
  • Raleigh Capital Management sold 72 Novo Nordisk shares in Q2 2026, an estimated $2.65K.
  • Raleigh Capital Management first reported a position in Novo Nordisk in Q1 2023 and held it in 9 quarters.
  • Raleigh Capital Management's Novo Nordisk position peaked at $13K in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Raleigh Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.